Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics, Inc. (RLAY) is a healthcare company (biotechnology) based in the United States. The share price is $16.93, down 2.00% on the day, which values the company at $3.74B. Price as of 17 Nov 2026, 17:29 UTC, from Yahoo Finance.

Key facts

Share price
$16.93−2.00% today
Market value
$3.74B
Funk Score
38/100
Against its own history
Well above its usual priceusual price $5.90
200-week average
$9.4879% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Relay Therapeutics, Inc. in more detail

RLAY trades at -10.8× next year's expected earnings, 361.3× sales. Measured against its own history, the price is 187% above what its usual multiples would imply ($5.90) — well above its usual price. It sits 79% above its 200-week average of $9.48.

Over the last five fiscal years Relay Therapeutics, Inc. has compounded revenue -28.6% a year. Its Funk Score is 38 out of 100 (financial strength 8.3, profitability 2.0, growth 4.7, value 0.0, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Share count keeps rising; Heavy stock-based pay.

3 of the superinvestors tracked here hold RLAY, including Julian and Felix Baker (0.3% of the portfolio), Louis Bacon (0.2% of the portfolio), Stanley Druckenmiller (0.1% of the portfolio).

Superinvestors holding RLAY

3 of the investors tracked here report a position in their latest 13F filing.

Relay Therapeutics, Inc. (RLAY): questions and answers

What is Relay Therapeutics, Inc.'s market cap?

Relay Therapeutics, Inc. is valued at $3.74B at a share price of $16.93.

Is RLAY overvalued or undervalued?

Against its own history, RLAY is well above its usual price: the price is 187% above the $5.90 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is RLAY above its 200-week moving average?

Yes. RLAY is 78.6% above its 200-week average of $9.48. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Relay Therapeutics, Inc. growing?

Over the last five fiscal years Relay Therapeutics, Inc.'s revenue grew -28.6% a year.

Does RLAY pay a dividend?

Relay Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own RLAY?

In their latest quarterly filings, Julian and Felix Baker (0.3% of the portfolio), Louis Bacon (0.2% of the portfolio), Stanley Druckenmiller (0.1% of the portfolio) hold RLAY. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Relay Therapeutics, Inc. (RLAY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RLAY

Underlying data: Yahoo Finance; company filings with the SEC.